Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03674827 · ClinicalTrials.gov registry record · Phase 1
Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03674827 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 36 participants.
The verdict
NCT03674827, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
Part 1of the study will evaluate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of increasing doses of a vaccine-based immunotherapy regimen (VBIR-2) for patients with advanced or metastatic non-small cell lung cancer and metastatic triple-negative breast cancer. Part 2 will evaluate the safety, pharmacokinetics and pharmacodynamics, immunogenicity and preliminary evidence of efficacy of the Expansion dose of VBIR-2 in participants with advanced or metastatic non-small cell lung cancer.
Interventions
- BIOLOGICAL PF-06936308
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2021-09-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03674827
The ClinicalTrials.gov registry entry for NCT03674827 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06936308 is the first listed.
NCT03674827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03674827 about?
NCT03674827 is a clinical study titled "Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC". Part 1of the study will evaluate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of increasing doses of a vaccine-based immunotherapy regimen (VBIR-2) for patients with advanced or metastatic non-small cell lung cancer and metastatic triple-negative breast cancer. Part 2 will eval...
What is the current status of trial NCT03674827?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-11-27. Estimated completion is 2021-09-27.
What interventions are being tested in trial NCT03674827?
The interventions under investigation include: PF-06936308 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03674827?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.